Charles Jillings, CEO of Utilico, energized by strong economic momentum across Latin America. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksByotrol Regulatory News (BYOT)

Share Price Information for Byotrol (BYOT)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 0.125
Bid: 0.05
Ask: 0.20
Change: 0.00 (0.00%)
Spread: 0.15 (300.00%)
Open: 0.125
High: 0.125
Low: 0.125
Prev. Close: 0.125
BYOT Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Posting of Accounts, Notice of AGM and Restoration

11 Oct 2019 15:00

RNS Number : 6720P
Byotrol PLC
11 October 2019
 

 

 

Byotrol plc

 

("Byotrol" or the "Company")

.

Posting of audited accounts for the year ended 31 March 2019

Notice of Annual General Meeting

Restoration of trading on AIM

 

The Company announces that the Annual Report and Accounts ("Annual Report") for the year ended 31 March 2019 are now available on the Company's website at www.byotrol.co.uk, along with a Notice of Annual General Meeting ("AGM") and related Form of Proxy. Paper copies will be posted to shareholders by Friday 18 October.

Following final audit review processes the Board became aware of an adjustment required relating to the amount reported in the preliminary results as a financing charge for the year on contingent liabilities arising from the acquisition of Medimark. This adjustment has resulted in a reduction in the finance expense of £0.11m with a consequent increase in the fair value of contingent consideration recognised at the date of acquisition and a corresponding amount of goodwill.

There has been no effect on reported EBITDA or operating profit, and the underlying financial performance of the Byotrol Group for the year ended 31 March 2019 remains unchanged

 

Qualified audit report

 

Shareholders will note that the Annual Report contains a qualified audit opinion, with relevant wording as follows:

"Included within the Group cash and cash equivalents balance was £89,000 across four Lloyds Bank Plc accounts within two subsidiary entities. We have not received a response from Lloyds Bank Plc to our request for confirmation of bank account balances and of any other facilities or arrangements that the Group has with Lloyds Bank Plc other than an acknowledgement of receipt, which confirms that an account previously held by the parent company with a trivial balance recognised in the Company statement of financial position is closed."

"We were able to review bank reconciliations for three of the four open Lloyds Bank Plc accounts referred to above, with the fourth account having a trivial balance for which bank statements indicate trivial movement during the year. However we were unable to perform all our planned audit procedures and we considered that alternative audit procedures did not fully address the risk of completeness of bank facilities across the Group and parent company financial statements."

 

The Directors have made every effort to resolve this matter to our auditor's satisfaction, without success. Whilst it may have been possible eventually to obtain a suitable response, the length of time this may have required was indeterminate, and the Board took the decision that the interests of shareholders were best served by publishing the accounts with the consequential qualified audit opinion but resulting in the lifting in the suspension from trading on AIM. Since the year end we have transferred over £86,000 of the aggregate amount from the bank concerned to another commercial bank and intend to transfer the balance shortly.

 

The Company's AGM will be held at the offices of finnCap in London on Thursday 14th November at 10am.

 

Following the release of these final audited results, the Company announces that the suspension of the Company's ordinary shares of 1 pence each ("Ordinary Shares") from trading on AIM will be lifted and trading in the Company's Ordinary Shares on AIM is expected to recommence immediately from 3:00pm on 11 October 2019.

 

 

Enquiries:

 

 

Byotrol plc 01925 742 000

David Traynor - Chief Executive

Nic Hellyer - Chief Financial Officer

 

finnCap

Geoff Nash / Teddy Whiley - Corporate Finance 020 7220 0500

Richard Chambers - ECM

 

 

Notes to Editors:

 

 

Byotrol plc (BYOT.L), quoted on AIM, is a specialist developer of antimicrobial technologies, identifying, developing, formulating and commercialising cutting-edge antimicrobial solutions.

 

Our patented suite of technologies deliver powerful, broad-spectrum efficacy, optimised against commonly-occurring and industry-specific pathogens.

 

Founded in 2005, the Company seeks to develop and commercialise advanced antimicrobial technologies that create easier, safer and cleaner lives for everyone.

 

For more information, please go to www.byotrol.co.uk

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
ACSUAOORKWARAAA
Date   Source Headline
23rd Apr 20246:00 pmRNSByotrol
22nd Apr 20244:44 pmRNSCapital Reorganisation Delay
22nd Apr 20241:27 pmRNSResults of General Meeting
15th Apr 202411:48 amRNSHolding(s) in Company
8th Apr 20247:00 amRNSHolding(s) in Company
2nd Apr 20243:27 pmRNSDirector Dealing
28th Mar 20247:00 amRNSProposed Cancellation
22nd Dec 202311:44 amRNSHolding(s) in Company
7th Dec 20237:00 amRNSHalf-year Report
14th Nov 20237:00 amRNSLaunch of PROCESSUS® Instrument Decontamination
14th Nov 20237:00 amRNSTrading Update
9th Nov 20233:43 pmRNSHolding(s) in Company
27th Sep 20237:00 amRNSBoard Changes
13th Sep 20233:33 pmRNSResult of AGM
8th Sep 20234:33 pmRNSDirector Dealing
7th Sep 20237:01 amRNSBoard Appointment
7th Sep 20237:00 amRNSTrading Update
29th Aug 20238:51 amRNSLaunch of CHEMGENE MEDLAB into human healthcare
23rd Aug 20237:00 amRNSInvestor Presentation via Investor Meet Company
31st Jul 20237:00 amRNSFinal Results
6th Jul 20237:00 amRNSPatent Grant for Novel Anti-viral Seaweed Extract
24th May 20233:14 pmRNSUS EPA approves Byotrol24 as long-lasting virucide
24th May 20238:51 amRNSDirector Dealing
28th Apr 20239:57 amRNSDirector Dealing
27th Apr 20237:00 amRNSTrading Update and Board Changes
1st Feb 20239:52 amRNSDirector Dealing
22nd Dec 20223:08 pmRNSDirector Dealing
19th Dec 202210:00 amRNSDirector Dealing
16th Dec 20227:00 amRNSGrant of Share Incentive Awards
12th Dec 20227:00 amRNSInterim results and Investor Presentation
22nd Nov 20227:00 amRNSDirectorate Changes
27th Sep 202211:15 amRNSPDMR Shareholding
22nd Sep 20225:21 pmRNSResult of AGM
8th Sep 20227:00 amRNSDirector Dealing
2nd Sep 202210:02 amRNSInvestor Presentation
30th Aug 20227:00 amRNSFinal Results
12th Aug 20223:30 pmRNSDirector Dealing
28th Jul 20227:00 amRNSCompletion of Convertible Loan Note Fundraising
11th Jul 20227:00 amRNSTrading Update and Notice of Results
22nd Apr 20229:14 amRNSHolding(s) in Company
2nd Mar 20227:00 amRNSTrading Update
12th Jan 20227:00 amRNSSenior Management Appointment
14th Dec 20219:06 amRNSSecond Price Monitoring Extn
14th Dec 20219:00 amRNSPrice Monitoring Extension
13th Dec 20217:00 amRNSDirectorate Change
9th Dec 20218:51 amRNSDirector Dealing
8th Dec 20217:00 amRNSInterim Results and Investor Presentation
2nd Nov 20217:00 amRNSDirectorate and Senior Management Changes
1st Nov 202111:36 amRNSTotal Voting Rights
1st Nov 202111:20 amRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.